piracetam has been researched along with Epilepsies, Myoclonic in 42 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Epilepsies, Myoclonic: A clinically diverse group of epilepsy syndromes characterized either by myoclonic seizures or by myoclonus in association with other seizure types. Myoclonic epilepsy syndromes are divided into three subtypes based on etiology: familial, cryptogenic, and symptomatic.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Herein, we describe two young men with epilepsy who experienced severe loss of libido and anhedonia after levetiracetam intake." | 7.78 | Levetiracetam-associated loss of libido and anhedonia. ( Bramanti, P; Calabrò, RS; Italiano, D; Militi, D, 2012) |
| "We present the first reported case of a rapid clinical and electroencephalographic response to intravenous levetiracetam infusion of myoclonic status epilepticus in a patient with progressive myoclonus epilepsy due to Gaucher disease." | 7.78 | Gaucher disease: successful treatment of myoclonic status epilepticus with levetiracetam. ( Knight, EM; Lenz, T; Tuxhorn, I; Vaca, GF, 2012) |
| "Since its introduction in 2006, 43 patients with various forms of status epilepticus (SE) have been treated with the intravenous formulation of levetiracetam (LEV) in our clinic." | 7.75 | Two years of experience in the treatment of status epilepticus with intravenous levetiracetam. ( Eue, S; Grumbt, M; Müller, M; Schulze, A, 2009) |
| "We report on a 3-year-old boy with myoclonic-astatic epilepsy who developed myoclonic status epilepticus with continuous twitching of the face and unresponsiveness under monotherapy with levetiracetam." | 7.73 | Levetiracetam-induced myoclonic status epilepticus in myoclonic-astatic epilepsy: a case report. ( Krämer, G; Kröll-Seger, J; Mothersill, IW; Novak, S; Sälke-Kellermann, RA, 2006) |
| "Levetiracetam was well tolerated (mean dose: 1985 mg/day)." | 6.73 | A pilot trial of levetiracetam in eyelid myoclonia with absences (Jeavons syndrome). ( Biondi, R; Capovilla, G; Coppola, A; Di Bonaventura, C; Fontanillas, L; Giallonardo, AT; Romeo, A; Rubboli, G; Sofia, V; Striano, P; Striano, S; Viri, M; Vitale, G; Zara, F, 2008) |
| "Levetiracetam-treated cats had higher freedom from myoclonic seizures (50." | 5.46 | Levetiracetam in the management of feline audiogenic reflex seizures: a randomised, controlled, open-label study. ( Bessant, C; Garosi, L; Harvey, RJ; Lowrie, M; Sparkes, A; Thomson, S, 2017) |
| "Late Onset Myoclonic Epilepsy in Down Syndrome (LOMEDS) is a recognized entity usually preceded by cognitive deterioration." | 5.36 | Improvement of myoclonic epilepsy in Down syndrome treated with levetiracetam. ( Amina, S; Koubeissi, M; Sangani, M; Shahid, A, 2010) |
| " Repeat video-EEG 2 months after initiation of levetiracetam treatment disclosed a >95% decrease in frequency of myoclonic seizures, and absence seizures were no longer evident." | 3.88 | Absence Seizures as a Feature of Juvenile Myoclonic Epilepsy in Rhodesian Ridgeback Dogs. ( Cortez, MA; Fischer, A; James, FMK; Kluger, G; Lohi, H; Neßler, JN; Tipold, A; Wielaender, F, 2018) |
| " Herein, we describe two young men with epilepsy who experienced severe loss of libido and anhedonia after levetiracetam intake." | 3.78 | Levetiracetam-associated loss of libido and anhedonia. ( Bramanti, P; Calabrò, RS; Italiano, D; Militi, D, 2012) |
| "We present the first reported case of a rapid clinical and electroencephalographic response to intravenous levetiracetam infusion of myoclonic status epilepticus in a patient with progressive myoclonus epilepsy due to Gaucher disease." | 3.78 | Gaucher disease: successful treatment of myoclonic status epilepticus with levetiracetam. ( Knight, EM; Lenz, T; Tuxhorn, I; Vaca, GF, 2012) |
| "We present a patient with cryptogenic focal epilepsy and another with Dravet syndrome, who experienced seizure aggravation and negative myoclonus, associated with continuous spikes and waves during slow sleep, induced by levetiracetam." | 3.76 | Levetiracetam-induced seizure aggravation associated with continuous spikes and waves during slow sleep in children with refractory epilepsies. ( Caraballo, RH; Cersósimo, R; De los Santos, C, 2010) |
| "Since its introduction in 2006, 43 patients with various forms of status epilepticus (SE) have been treated with the intravenous formulation of levetiracetam (LEV) in our clinic." | 3.75 | Two years of experience in the treatment of status epilepticus with intravenous levetiracetam. ( Eue, S; Grumbt, M; Müller, M; Schulze, A, 2009) |
| "We report on a 3-year-old boy with myoclonic-astatic epilepsy who developed myoclonic status epilepticus with continuous twitching of the face and unresponsiveness under monotherapy with levetiracetam." | 3.73 | Levetiracetam-induced myoclonic status epilepticus in myoclonic-astatic epilepsy: a case report. ( Krämer, G; Kröll-Seger, J; Mothersill, IW; Novak, S; Sälke-Kellermann, RA, 2006) |
| "Levetiracetam (LEV) was chosen based on clinical evidence." | 2.77 | The effect of levetiracetam on focal nocturnal epileptiform activity during sleep--a placebo-controlled double-blind cross-over study. ( Bakke, KA; Bjørnæs, H; Brager-Larsen, L; Eriksson, AS; Heminghyt, E; Larsson, PG; Rytter, E, 2012) |
| "Levetiracetam was orally administrated at starting dose of approximately 10 mg/kg/day up to 50 to 60 mg/kg/day in two doses." | 2.73 | An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. ( Beccaria, F; Besana, D; Capovilla, G; Ciampa, C; Coppola, A; Coppola, GG; Elia, M; Gaggero, R; Gennaro, E; Granata, T; Mancardi, MM; Pezzella, M; Ragona, F; Rasmini, P; Specchio, N; Striano, P; Striano, S; Vecchi, M; Vigevano, F; Viri, M; Zara, F, 2007) |
| "Levetiracetam was well tolerated (mean dose: 1985 mg/day)." | 2.73 | A pilot trial of levetiracetam in eyelid myoclonia with absences (Jeavons syndrome). ( Biondi, R; Capovilla, G; Coppola, A; Di Bonaventura, C; Fontanillas, L; Giallonardo, AT; Romeo, A; Rubboli, G; Sofia, V; Striano, P; Striano, S; Viri, M; Vitale, G; Zara, F, 2008) |
| "Levetiracetam-treated patients were more likely to respond to treatment than patients receiving placebo (OR = 4." | 2.73 | Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. ( Andermann, E; Andermann, F; Gough, WB; Meyvisch, P; Noachtar, S; Schiemann-Delgado, J, 2008) |
| "Levetiracetam was recently approved as adjunctive therapy for partial onset seizures." | 2.70 | A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. ( Chuang, C; Fahn, S; Frucht, SJ; Louis, ED, 2001) |
| " More patients showed clinically relevant improvement with the highest dosage and, in individual patients, increasing the dose improved response." | 2.69 | Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. ( Hakamies, L; Koskiniemi, M; Lamusuo, S; Taalas, J; Van Vleymen, B, 1998) |
| "Progressive myoclonus epilepsy is a syndrome confused with myoclonic seizures and other epilepsies." | 2.38 | The clinical challenge of progressive myoclonus epilepsy. ( Tate, E, 1993) |
| "Levetiracetam-treated cats had higher freedom from myoclonic seizures (50." | 1.46 | Levetiracetam in the management of feline audiogenic reflex seizures: a randomised, controlled, open-label study. ( Bessant, C; Garosi, L; Harvey, RJ; Lowrie, M; Sparkes, A; Thomson, S, 2017) |
| "In addition, the effect on seizure count was compared with that of various AED regimen and the vagus nerve stimulation (VNS)." | 1.42 | Efficacy and tolerability of the ketogenic diet in Dravet syndrome - Comparison with various standard antiepileptic drug regimen. ( Benninger, F; Dressler, A; Feucht, M; Grassl, R; Gröppel, G; Mühlebner, A; Reiter-Fink, E; Reithofer, E; Trimmel-Schwahofer, P, 2015) |
| "Levetiracetam is a broad spectrum antiepileptic drug (AED) with proven efficacy when used as adjunctive therapy against myoclonic seizures." | 1.42 | Paradoxical exacerbation of myoclonic-astatic seizures by levetiracetam in myoclonic astatic epilepsy. ( Beydoun, A; Fawaz, A; Hmaimess, G; Makke, Y; Nasreddine, W, 2015) |
| "The seizures were unresponsive to bolus midazolam, phenytoin infusion and levetiracetam infusion." | 1.42 | A rare cause of status epilepticus; alpha lipoic acid intoxication, case report and review of the literature. ( Çelik, T; Çelik, Ü; Gezgin, AE; Kaya, MS; Kömür, M; Tolunay, O, 2015) |
| "Late Onset Myoclonic Epilepsy in Down Syndrome (LOMEDS) is a recognized entity usually preceded by cognitive deterioration." | 1.36 | Improvement of myoclonic epilepsy in Down syndrome treated with levetiracetam. ( Amina, S; Koubeissi, M; Sangani, M; Shahid, A, 2010) |
| "Levetiracetam is a broad spectrum anti-epileptic drug with renal elimination and no hepatic metabolism." | 1.35 | Levetiracetam accumulation in renal failure causing myoclonic encephalopathy with triphasic waves. ( Iwanowski, P; Jallon, P; Landis, T; Vulliemoz, S, 2009) |
| "The anti-seizure activity of both compounds occurred 30 min following intraperitoneal (i." | 1.34 | Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus. ( Tai, KK; Truong, DD, 2007) |
| "Levetiracetam was titrated up to an optimal dosage for every individual patient, depending on efficacy and tolerability, and reflecting clinical practice." | 1.33 | Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial. ( Buyse, G; Ceulemans, B; Lagae, L, 2005) |
| "Levetiracetam is a new antiepileptic drug with a broad-spectrum activity that includes efficacy against positive myoclonus." | 1.32 | Dramatic effect of levetiracetam on epileptic negative myoclonus. ( Baldy-Moulinier, M; Crespel, A; Gelisse, P; Genton, P, 2003) |
| "Piracetam has been shown to be a very potent antimyoclonic agent, but only at very high, impractical doses, ranging from 24 to 40 g/d." | 1.31 | Antimyoclonic effect of levetiracetam. ( Gélisse, P; Genton, P, 2000) |
| "In patients with progressive myoclonus epilepsy, the efficacy of the drug increased during the first 12 months of treatment and then stabilized." | 1.31 | Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. ( Andermann, E; Andermann, F; D'Agostino, D; Dubeau, F; Fedi, M; Reutens, D, 2001) |
| "Sixty patients with disabling myoclonus excluding mainly spinal myoclonus were treated by piracetam as an open-labeled study, and myoclonus score, neurological symptoms, functional disability, and intensity of myoclonus were scored before and after treatment, including a blinded video inspection." | 1.29 | Clinical trial of piracetam in patients with myoclonus: nationwide multiinstitution study in Japan. The Myoclonus/Piracetam Study Group. ( Ikeda, A; Kimura, J; Mizuno, Y; Shibasaki, H; Tashiro, K, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.38) | 18.7374 |
| 1990's | 7 (16.67) | 18.2507 |
| 2000's | 17 (40.48) | 29.6817 |
| 2010's | 17 (40.48) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wielaender, F | 1 |
| James, FMK | 1 |
| Cortez, MA | 1 |
| Kluger, G | 1 |
| Neßler, JN | 1 |
| Tipold, A | 1 |
| Lohi, H | 1 |
| Fischer, A | 1 |
| Dressler, A | 1 |
| Trimmel-Schwahofer, P | 1 |
| Reithofer, E | 1 |
| Mühlebner, A | 1 |
| Gröppel, G | 1 |
| Reiter-Fink, E | 1 |
| Benninger, F | 1 |
| Grassl, R | 1 |
| Feucht, M | 1 |
| Aller-Alvarez, JS | 1 |
| Menéndez-González, M | 1 |
| Ribacoba-Montero, R | 1 |
| Salvado, M | 1 |
| Vega, V | 1 |
| Suárez-Moro, R | 1 |
| Sueiras, M | 1 |
| Toledo, M | 1 |
| Salas-Puig, J | 1 |
| Álvarez-Sabin, J | 1 |
| Inoue, S | 1 |
| Yazawa, S | 1 |
| Murahara, T | 1 |
| Yamauchi, R | 1 |
| Shimohama, S | 1 |
| Makke, Y | 1 |
| Hmaimess, G | 1 |
| Nasreddine, W | 1 |
| Fawaz, A | 1 |
| Beydoun, A | 1 |
| Tolunay, O | 1 |
| Çelik, T | 1 |
| Kömür, M | 1 |
| Gezgin, AE | 1 |
| Kaya, MS | 1 |
| Çelik, Ü | 1 |
| Lowrie, M | 1 |
| Thomson, S | 1 |
| Bessant, C | 1 |
| Sparkes, A | 1 |
| Harvey, RJ | 1 |
| Garosi, L | 1 |
| Vulliemoz, S | 1 |
| Iwanowski, P | 1 |
| Landis, T | 1 |
| Jallon, P | 1 |
| Cáceres-Agra, JJ | 1 |
| Santana-Cabrera, L | 1 |
| Fernández-Arroyo, M | 1 |
| Sánchez-Palacios, M | 1 |
| Eue, S | 1 |
| Grumbt, M | 1 |
| Müller, M | 1 |
| Schulze, A | 1 |
| Sangani, M | 1 |
| Shahid, A | 1 |
| Amina, S | 1 |
| Koubeissi, M | 1 |
| Caraballo, RH | 1 |
| Cersósimo, R | 1 |
| De los Santos, C | 1 |
| Vaamonde-Gamo, J | 1 |
| Martinez-Palomeque, G | 1 |
| Alvarez-Soria, MJ | 1 |
| Flores-Barragan, JM | 1 |
| Ibanez, R | 1 |
| Cabello-De la Rosa, JP | 1 |
| Gentile, V | 1 |
| Brunetto, D | 1 |
| Leo, I | 1 |
| Bonetti, S | 1 |
| Verrotti, A | 1 |
| Franzoni, E | 1 |
| Vrielynck, P | 1 |
| Rostomashvili, N | 1 |
| Degroote, E | 1 |
| Ghariani, S | 1 |
| van Rijckevorsel, K | 1 |
| Kobayashi, K | 1 |
| Takeuchi, A | 1 |
| Oka, M | 1 |
| Akiyama, M | 1 |
| Ohtsuka, Y | 1 |
| Larsson, PG | 1 |
| Bakke, KA | 1 |
| Bjørnæs, H | 1 |
| Heminghyt, E | 1 |
| Rytter, E | 1 |
| Brager-Larsen, L | 1 |
| Eriksson, AS | 1 |
| Calabrò, RS | 1 |
| Italiano, D | 1 |
| Militi, D | 1 |
| Bramanti, P | 1 |
| Vaca, GF | 1 |
| Lenz, T | 1 |
| Knight, EM | 1 |
| Tuxhorn, I | 1 |
| Liu, YH | 1 |
| Wang, XL | 1 |
| Deng, YC | 1 |
| Zhao, G | 1 |
| Gelisse, P | 3 |
| Crespel, A | 1 |
| Genton, P | 4 |
| Baldy-Moulinier, M | 1 |
| Lagae, L | 1 |
| Buyse, G | 1 |
| Ceulemans, B | 1 |
| Labate, A | 1 |
| Colosimo, E | 1 |
| Gambardella, A | 1 |
| Leggio, U | 1 |
| Ambrosio, R | 1 |
| Quattrone, A | 1 |
| Kröll-Seger, J | 1 |
| Mothersill, IW | 1 |
| Novak, S | 1 |
| Sälke-Kellermann, RA | 1 |
| Krämer, G | 1 |
| Berger, A | 1 |
| Schroeter, C | 1 |
| Wiemer-Kruel, A | 1 |
| Strobl, K | 1 |
| Hoffmann, GF | 1 |
| Rating, D | 1 |
| Lebon, P | 1 |
| Ernst, JP | 1 |
| Wolf, NI | 1 |
| Striano, P | 2 |
| Coppola, A | 2 |
| Pezzella, M | 1 |
| Ciampa, C | 1 |
| Specchio, N | 1 |
| Ragona, F | 1 |
| Mancardi, MM | 1 |
| Gennaro, E | 1 |
| Beccaria, F | 1 |
| Capovilla, G | 2 |
| Rasmini, P | 1 |
| Besana, D | 1 |
| Coppola, GG | 1 |
| Elia, M | 1 |
| Granata, T | 1 |
| Vecchi, M | 1 |
| Vigevano, F | 1 |
| Viri, M | 2 |
| Gaggero, R | 1 |
| Striano, S | 2 |
| Zara, F | 2 |
| Kilaru, S | 1 |
| Bergqvist, AGC | 1 |
| Tai, KK | 1 |
| Truong, DD | 1 |
| Sofia, V | 1 |
| Rubboli, G | 1 |
| Di Bonaventura, C | 1 |
| Vitale, G | 1 |
| Fontanillas, L | 1 |
| Giallonardo, AT | 1 |
| Biondi, R | 1 |
| Romeo, A | 1 |
| Noachtar, S | 1 |
| Andermann, E | 2 |
| Meyvisch, P | 1 |
| Andermann, F | 2 |
| Gough, WB | 1 |
| Schiemann-Delgado, J | 1 |
| Tate, E | 1 |
| Brown, P | 1 |
| Steiger, MJ | 1 |
| Thompson, PD | 1 |
| Rothwell, JC | 1 |
| Day, BL | 1 |
| Salama, M | 1 |
| Waegemans, T | 1 |
| Marsden, CD | 1 |
| Larner, AJ | 1 |
| Heafield, MT | 1 |
| Ikeda, A | 1 |
| Shibasaki, H | 1 |
| Tashiro, K | 1 |
| Mizuno, Y | 1 |
| Kimura, J | 1 |
| Koskiniemi, M | 1 |
| Van Vleymen, B | 1 |
| Hakamies, L | 1 |
| Lamusuo, S | 1 |
| Taalas, J | 1 |
| Fedi, M | 1 |
| Reutens, D | 1 |
| Dubeau, F | 1 |
| D'Agostino, D | 1 |
| Frucht, SJ | 1 |
| Louis, ED | 1 |
| Chuang, C | 1 |
| Fahn, S | 1 |
| Guerrini, R | 1 |
| Paulus, W | 1 |
| Ried, S | 1 |
| Stodieck, SR | 1 |
| Schmidt, D | 1 |
| Obeso, JA | 1 |
| Artieda, J | 1 |
| Luquin, MR | 1 |
| Vaamonde, J | 1 |
| Martínez Lage, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Levetiracetam Treatment of Neonatal Seizures: A Multi-Centre Randomized Blinded Controlled Study of the Efficacy of Oral Levetiracetam as First Line Treatment for Neonatal Seizures in China[NCT02550028] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2015-09-01 | Terminated (stopped due to The study was concluded as planned upon reaching its predetermined endpoint, which included the completion of data collection and achievement of the necessary sample size for statistical significance.) | ||
| A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Levetiracetam (LEV) (Oral Tablets of 500 mg b.i.d.) at a Dose of 3000 mg/Day as Adjunctive Treatment in Adolescents (≥ 12 Years) and Adults (≤ 65 Year[NCT00150774] | Phase 3 | 116 participants | Interventional | 2001-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for piracetam and Epilepsies, Myoclonic
| Article | Year |
|---|---|
The clinical challenge of progressive myoclonus epilepsy.
Topics: 5-Hydroxytryptophan; Child; Epilepsies, Myoclonic; Female; Humans; Piracetam; Quality of Life | 1993 |
8 trials available for piracetam and Epilepsies, Myoclonic
| Article | Year |
|---|---|
The effect of levetiracetam on focal nocturnal epileptiform activity during sleep--a placebo-controlled double-blind cross-over study.
Topics: Analysis of Variance; Anticonvulsants; Child; Cross-Over Studies; Double-Blind Method; Drug Administ | 2012 |
Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Epilepsies, | 2006 |
An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy.
Topics: Adolescent; Adult; Child; Child, Preschool; Epilepsies, Myoclonic; Female; Follow-Up Studies; Humans | 2007 |
A pilot trial of levetiracetam in eyelid myoclonia with absences (Jeavons syndrome).
Topics: Adolescent; Adult; Anticonvulsants; Child; Comorbidity; Drug Therapy, Combination; Epilepsies, Myocl | 2008 |
Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Chi-Square Distribution; Child; Double-Blind Method; Epile | 2008 |
Effectiveness of piracetam in cortical myoclonus.
Topics: Adult; Aged; Anticonvulsants; Cerebral Cortex; Double-Blind Method; Drug Therapy, Combination; Elect | 1993 |
Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo.
Topics: Activities of Daily Living; Administration, Oral; Adolescent; Adult; Cross-Over Studies; Disease Pro | 1998 |
A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus.
Topics: Adult; Aged; Anticonvulsants; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration | 2001 |
33 other studies available for piracetam and Epilepsies, Myoclonic
| Article | Year |
|---|---|
Absence Seizures as a Feature of Juvenile Myoclonic Epilepsy in Rhodesian Ridgeback Dogs.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Electroencephalography; Epilepsies, Myoclonic; Female; | 2018 |
Efficacy and tolerability of the ketogenic diet in Dravet syndrome - Comparison with various standard antiepileptic drug regimen.
Topics: Adolescent; Anticonvulsants; Benzodiazepines; Bromides; Child; Child, Preschool; Clobazam; Diet, Ket | 2015 |
Myoclonic epilepsy in Down syndrome and Alzheimer disease.
Topics: Adult; Aged; Alzheimer Disease; Anticonvulsants; Down Syndrome; Electroencephalography; Epilepsies, | 2017 |
[Dramatic seizure reduction with levetiracetam in adult Dravet syndrome: a case report].
Topics: Adult; Drug Therapy, Combination; Epilepsies, Myoclonic; Humans; Levetiracetam; Male; Piracetam; Sta | 2015 |
Paradoxical exacerbation of myoclonic-astatic seizures by levetiracetam in myoclonic astatic epilepsy.
Topics: Anticonvulsants; Child, Preschool; Epilepsies, Myoclonic; Female; Humans; Infant; Levetiracetam; Mal | 2015 |
A rare cause of status epilepticus; alpha lipoic acid intoxication, case report and review of the literature.
Topics: Anticonvulsants; Epilepsies, Myoclonic; Female; Humans; Infant; Levetiracetam; Midazolam; Piracetam; | 2015 |
Levetiracetam in the management of feline audiogenic reflex seizures: a randomised, controlled, open-label study.
Topics: Animals; Anticonvulsants; Cat Diseases; Cats; Epilepsies, Myoclonic; Epilepsy, Generalized; Female; | 2017 |
Levetiracetam accumulation in renal failure causing myoclonic encephalopathy with triphasic waves.
Topics: Aged, 80 and over; Anticonvulsants; Electroencephalography; Epilepsies, Myoclonic; Female; Humans; L | 2009 |
[Levetiracetam use in the post-hypoxic myoclonic status].
Topics: Anticonvulsants; Epilepsies, Myoclonic; Humans; Hypoxia, Brain; Levetiracetam; Piracetam; Prospectiv | 2009 |
Two years of experience in the treatment of status epilepticus with intravenous levetiracetam.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Cerebrovascular Disorders; Epilepsies, | 2009 |
Improvement of myoclonic epilepsy in Down syndrome treated with levetiracetam.
Topics: Adult; Alzheimer Disease; Anticonvulsants; Disease Progression; Dose-Response Relationship, Drug; Do | 2010 |
Levetiracetam-induced seizure aggravation associated with continuous spikes and waves during slow sleep in children with refractory epilepsies.
Topics: Anticonvulsants; Child; Drug Therapy, Combination; Electroencephalography; Epilepsies, Myoclonic; Ep | 2010 |
[Myoclonias with a propiospinal and radicular origin: their response to levetiracetam].
Topics: Anticonvulsants; Epilepsies, Myoclonic; Female; Humans; Levetiracetam; Piracetam; Young Adult | 2010 |
Clinical and neuropsychological considerations in a case of unrecognized myoclonic epileptic jerks dramatically controlled by levetiracetam.
Topics: Anticonvulsants; Child; Cognition Disorders; Electroencephalography; Epilepsies, Myoclonic; Female; | 2010 |
Perioral myoclonia with absences and myoclonic status aggravated by oxcarbazepine.
Topics: Anticonvulsants; Brain; Carbamazepine; Child; Electroencephalography; Epilepsies, Myoclonic; Epileps | 2011 |
Amelioration of disabling myoclonus in a case of DRPLA by levetiracetam.
Topics: Adolescent; Anticonvulsants; Epilepsies, Myoclonic; Humans; Levetiracetam; Male; Myoclonic Epilepsie | 2012 |
Levetiracetam-associated loss of libido and anhedonia.
Topics: Adult; Anhedonia; Anticonvulsants; Brain; Electroencephalography; Epilepsies, Myoclonic; Epilepsy, C | 2012 |
Gaucher disease: successful treatment of myoclonic status epilepticus with levetiracetam.
Topics: Adolescent; Anticonvulsants; Electroencephalography; Epilepsies, Myoclonic; Gaucher Disease; Humans; | 2012 |
Levetiracetam-associated aggravation of myoclonic seizure in children.
Topics: Anticonvulsants; Child; Electroencephalography; Epilepsies, Myoclonic; Humans; Levetiracetam; Male; | 2012 |
Dramatic effect of levetiracetam on epileptic negative myoclonus.
Topics: Anticonvulsants; Electroencephalography; Epilepsies, Myoclonic; Female; Humans; Levetiracetam; Middl | 2003 |
Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Cohort Studies; Dose-Response Relationship, Dr | 2005 |
Levetiracetam-induced myoclonic status epilepticus in myoclonic-astatic epilepsy: a case report.
Topics: Anticonvulsants; Behavior; Child, Preschool; Electroencephalography; Electromyography; Epilepsies, M | 2006 |
Atypical case of Aicardi-Goutières syndrome with late-onset myoclonic status.
Topics: Adult; Basal Ganglia Diseases; Brain Diseases; Calcinosis; Comorbidity; Epilepsies, Myoclonic; Epile | 2007 |
Current treatment of myoclonic astatic epilepsy: clinical experience at the Children's Hospital of Philadelphia.
Topics: Age of Onset; Anticonvulsants; Child; Cognition Disorders; Dietary Fats; Electroencephalography; Epi | 2007 |
Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Epilepsies, Myoc | 2007 |
Post anoxic action myoclonus.
Topics: Clonazepam; Drug Therapy, Combination; Epilepsies, Myoclonic; Humans; Hypoxia; Male; Middle Aged; Pi | 1993 |
Clinical trial of piracetam in patients with myoclonus: nationwide multiinstitution study in Japan. The Myoclonus/Piracetam Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Disability Evaluation; Dose-Response Relationship, Dr | 1996 |
Antimyoclonic effect of levetiracetam.
Topics: Adult; Anticonvulsants; Epilepsies, Myoclonic; Female; Humans; Levetiracetam; Male; Middle Aged; Pir | 2000 |
Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Disability Evaluation; Disease Progression; Dose-Response Relati | 2001 |
Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Encephalitis; Epilepsies, Myoclonic; Humans; Hypo | 2001 |
Effect of alcohol on action myoclonus in Lance-Adams syndrome and progressive myoclonus epilepsy.
Topics: Alcohol Drinking; Drug Tolerance; Epilepsies, Myoclonic; Follow-Up Studies; Humans; Myoclonus; Pirac | 1992 |
Abolition of photoparoxysmal response in progressive myoclonus epilepsy.
Topics: Adolescent; Clonazepam; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electroencephal | 1991 |
Antimyoclonic action of piracetam.
Topics: Adolescent; Adult; Aged; Electroencephalography; Epilepsies, Myoclonic; Evoked Potentials, Somatosen | 1986 |